Targeting MDR-1 gene expression, BAX/BCL2, caspase-3, and Ki-67 by nanoencapsulated imatinib and hesperidin to enhance anticancer activity and ameliorate cardiotoxicity.
Saved in:
| Title: | Targeting MDR-1 gene expression, BAX/BCL2, caspase-3, and Ki-67 by nanoencapsulated imatinib and hesperidin to enhance anticancer activity and ameliorate cardiotoxicity. |
|---|---|
| Authors: | El-Sisi AE; Pharmacology and Toxicology department, College of Pharmacy, University of Tanta, Tanta, Egypt., Sokkar SS; Pharmacology and Toxicology department, College of Pharmacy, University of Tanta, Tanta, Egypt., Ibrahim HA; Pharmacology and Toxicology department, College of Pharmacy, University of Tanta, Tanta, Egypt., Hamed MF; Department of Pathology, College of Veterinary Medicine, University of El-Mansoura, Mansoura, Egypt., Abu-Risha SE; Pharmacology and Toxicology department, College of Pharmacy, University of Tanta, Tanta, Egypt. |
| Source: | Fundamental & clinical pharmacology [Fundam Clin Pharmacol] 2020 Aug; Vol. 34 (4), pp. 458-475. Date of Electronic Publication: 2020 Mar 12. |
| Publication Type: | Comparative Study; Journal Article |
| Journal Info: | Publisher: Blackwell Science Country of Publication: England NLM ID: 8710411 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1472-8206 (Electronic) Linking ISSN: 07673981 NLM ISO Abbreviation: Fundam Clin Pharmacol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
